Data / Research funding / Muscular Dystrophy
Muscular Dystrophy: 345 NIH awards ($329.5M) to 127 organizations
345 NIH awards ($329.5M) in the NIH spending category Muscular Dystrophy, to 127 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
345 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $4,927,507 | May 5, 2010 | August 31, 2025 | VANDENBORNE, KRISTA H | reporter.nih.gov |
| Novel therapeutics for FSHD | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $3,829,831 | September 10, 2008 | May 31, 2024 | EMERSON, CHARLES P. | reporter.nih.gov |
| Genetic modifiers of Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,704,232 | May 15, 2014 | July 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| Protein structural biophysics driving drug discovery for cardiac calcium transport regulation, producing translational advances and mechanistic insights | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,701,653 | May 1, 2020 | April 30, 2028 | THOMAS, DAVID D | reporter.nih.gov |
| Dystrophin Replacement | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,349,499 | April 1, 1991 | April 30, 2026 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Reprogramming and Directed Differentiation of Skeletal Muscle Cells from hPSCs | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,204,262 | September 20, 2013 | June 30, 2028 | PYLE, APRIL D | reporter.nih.gov |
| Chaperone Dysfunction in Myopathy: Connecting Yeast Genetics with Mouse Models | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,193,112 | August 1, 2015 | June 30, 2027 | TRUE-KROB, HEATHER L | reporter.nih.gov |
| IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,161,261 | August 1, 2024 | July 31, 2027 | STEDMAN, HANSELL H | reporter.nih.gov |
| A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,123,687 | September 20, 2021 | August 31, 2027 | SALEH, ANTHONY D | reporter.nih.gov |
| Cardiovascular Consequences of Duchenne and Becker Muscular Dystrophinopathies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,104,268 | September 1, 2021 | August 31, 2027 | WITMAN, MELISSA A.H. | reporter.nih.gov |
| Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,017,334 | April 15, 2023 | March 31, 2028 | JOHNSON, NICHOLAS ELWOOD | reporter.nih.gov |
| Clinical Trial Readiness for Children 0-5 years with Congenital Muscular Dystrophy Secondary to LAMA2 Mutations | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,998,564 | September 18, 2023 | August 31, 2028 | CONNOLLY, ANNE M | reporter.nih.gov |
| Preclinical studies of pluripotent stem cell-derived myogenic progenitors in non-human primates | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,948,443 | August 6, 2021 | December 31, 2026 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Costamere Defects in Muscular Dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,905,862 | February 1, 2005 | November 30, 2026 | ERVASTI, JAMES M | reporter.nih.gov |
| CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,896,188 | August 15, 2021 | July 31, 2026 | HARPER, SCOTT Q | reporter.nih.gov |
| Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $2,857,598 | September 30, 2003 | August 31, 2024 | THORNTON, CHARLES A | reporter.nih.gov |
| Cytoskeletal Interactions of Dystrophin | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,806,646 | July 15, 1994 | July 31, 2026 | ERVASTI, JAMES M | reporter.nih.gov |
| Three-model platform for understanding DMD epigenetic mechanisms and advancing small molecule therapies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,725,938 | February 4, 2021 | December 31, 2026 | MAVES, LISA | reporter.nih.gov |
| CRISPR-inhibition for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,634,755 | August 4, 2021 | June 30, 2027 | JONES, PETER L | reporter.nih.gov |
| Paracrine actions of fibroblasts promote pathologic cardiac myocyte remodeling in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,557,217 | July 1, 2021 | June 30, 2027 | WELC, STEVEN S | reporter.nih.gov |
| Pathogenic Alterations of the 3D Epigenetic Landscape in Dystrophin-Deficient Skeletal Muscles and Reversal by Dystrophin Re-Expression | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,541,743 | August 1, 2009 | May 31, 2027 | PURI, PIER LORENZO | reporter.nih.gov |
| Therapeutic strategies for microsatellite expansion diseases using RNA targeting | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,491,089 | September 22, 2017 | November 30, 2027 | YEO, EUGENE WEI-MING | reporter.nih.gov |
| The role of TGFβs and cFAPs in Cardiac Pathology from RNA Toxicity | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,404,853 | July 1, 2023 | May 31, 2027 | MAHADEVAN, MANI SUBRAMANIAM | reporter.nih.gov |
| Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,376,851 | September 1, 2020 | July 31, 2026 | KIM, DEOK-HO | reporter.nih.gov |
| Probing the activity of DUX4 in FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,367,457 | March 19, 2010 | July 31, 2030 | KYBA, MICHAEL | reporter.nih.gov |
| Mechanisms of DUX4 mediated FSHD pathology | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,366,738 | July 3, 2013 | December 31, 2025 | JONES, PETER L | reporter.nih.gov |
| Genetic and epigenetic mechanisms of FSHD pathogenesis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,340,177 | September 1, 2017 | May 31, 2027 | YOKOMORI, KYOKO | reporter.nih.gov |
| 3D Shearwave Elasticity Biomarker Development for Neuromuscular Disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,328,423 | April 1, 2022 | December 31, 2026 | NIGHTINGALE, KATHRYN RADABAUGH | reporter.nih.gov |
| Structural Dynamics of Molecular Motors and the Ribosome | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $2,309,360 | July 15, 2016 | January 2, 2024 | GOLDMAN, YALE E | reporter.nih.gov |
| A cross-species preclinical platform to enhance the translation of new medicines | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $2,306,784 | December 1, 2023 | November 30, 2026 | GEISSE, NICHOLAS ANDREW | reporter.nih.gov |
| Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,303,547 | August 20, 2024 | July 31, 2029 | STATLAND, JEFFREY | reporter.nih.gov |
| Mechanism of immune response to muscle-directed AAV gene transfer | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,292,756 | May 19, 2023 | April 30, 2028 | HERZOG, ROLAND W. | reporter.nih.gov |
| Cerebellar pathology in the absence of plasticity gating | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,290,342 | July 1, 2021 | April 30, 2026 | PUGH, JASON RICHARD | reporter.nih.gov |
| Decoding the mechanisms of cell-cell fusion - Renewal - 1 | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,246,895 | May 4, 2020 | April 30, 2030 | CHEN, ELIZABETH H | reporter.nih.gov |
| Identifying the RNA Splicing and Gene Expression Changes that Cause Congenital Myotonic Dystrophy (Renewal) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,243,012 | April 1, 2018 | July 31, 2029 | JOHNSON, NICHOLAS ELWOOD | reporter.nih.gov |
| Implications of Genetic Diversity in Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,200,578 | September 1, 2021 | August 31, 2026 | KEMALADEWI, DWI UTAMI | reporter.nih.gov |
| Design, Synthesis and Efficacy of New Small Molecule Therapeutics to Impede Myotonic Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,142,960 | May 1, 2022 | March 31, 2027 | BERGLUND, ANDREW | reporter.nih.gov |
| "Structural Dynamics of Molecular Motors and the Ribosome" The studies proposed will give basic information on gene expression, cellular development, and transport motor function in cell biology. | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $2,129,508 | July 15, 2016 | May 31, 2026 | GOLDMAN, YALE E | reporter.nih.gov |
| Extracellular RNA biomarkers of myotonic dystrophy type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $2,126,281 | June 15, 2021 | May 31, 2025 | WHEELER, THURMAN M | reporter.nih.gov |
| Thrombospondin 4 regulates adaptive ER stress responseRenewal - Resubmission - 1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,118,480 | January 1, 2011 | January 31, 2028 | MOLKENTIN, JEFFERY D | reporter.nih.gov |
| Activity and therapeutic antagonism of the TP receptor in cardiomyopathy of muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,092,461 | July 1, 2023 | June 30, 2027 | WEST, JAMES D | reporter.nih.gov |
| D4Z4 Coding Transcripts and FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,082,296 | September 1, 1998 | December 31, 2026 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| 5-methylcytosine oxidation in development and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,060,740 | May 15, 2021 | December 31, 2026 | PFEIFER, GERD P | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $2,060,218 | June 16, 2022 | May 31, 2024 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,054,966 | September 30, 2020 | August 31, 2025 | VILLALTA, SERGIO ARMANDO | reporter.nih.gov |
| Dual-specificity phosphatase action in muscle disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,052,152 | June 1, 2022 | April 30, 2027 | BENNETT, ANTON M | reporter.nih.gov |
| Deciphering mechanisms of myoblast fusion | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,041,209 | July 1, 2015 | June 30, 2026 | MILLAY, DOUGLAS PAUL | reporter.nih.gov |
| Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,025,915 | August 1, 2020 | April 30, 2026 | SPENCER, MELISSA JAN | reporter.nih.gov |
| Scramblases for protein glycosylation | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,015,483 | April 1, 2022 | March 31, 2027 | MENON, ANANT K | reporter.nih.gov |
| Structure-Function of Nucleo-Cytoplasmic Communication | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,012,215 | September 1, 2021 | August 31, 2026 | SCHWARTZ, THOMAS | reporter.nih.gov |
| Evolving High Potency AAV Vectors for Neuromuscular Genome Editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,992,277 | September 10, 2018 | July 31, 2024 | ASOKAN, ARAVIND | reporter.nih.gov |
| Convenient quantification of myopathic change in muscle via electrical impedance myography | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,969,728 | June 15, 2024 | May 31, 2027 | DICKINSON, DAVID P. | reporter.nih.gov |
| Role of Skeletal Muscle Lymphatics in Duchenne Muscular Dystrophy Regulation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,963,162 | May 24, 2022 | April 30, 2027 | MUTHUCHAMY, MARIAPPAN | reporter.nih.gov |
| RNA Processing-Mediated Mechanisms of CNS Dysfunction in Myotonic Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,958,676 | July 1, 2019 | June 30, 2025 | WANG, ERIC T | reporter.nih.gov |
| Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $1,953,245 | April 1, 2015 | August 31, 2026 | WUEBBLES, RYAN DAVID | reporter.nih.gov |
| Interdependency of fibroadipogenic progenitors and extracellular matrix that drive skeletal muscle fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,940,024 | April 5, 2022 | March 31, 2027 | SMITH, LUCAS R | reporter.nih.gov |
| Mechanisms of resealing and rebuilding in muscle repair | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,879,250 | July 1, 2003 | April 30, 2028 | MCNALLY, ELIZABETH M | reporter.nih.gov |
| Mechanisms of Skeletal Muscle Pathogenesis in Myotonic Dystrophy Type 1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,864,085 | September 6, 2023 | August 31, 2028 | COOPER, THOMAS A | reporter.nih.gov |
| Deciphering the roles of FXR1 in health and myopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,854,831 | August 1, 2022 | July 31, 2026 | GREGORIO, CAROL C | reporter.nih.gov |
| Mechanism of Skeletal Muscle Calcium Dysregulation in Myotonic Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,832,760 | August 8, 2022 | June 30, 2027 | LUECK, JOHN D. | reporter.nih.gov |
| The Role of Lipin1 in Myofiber Stability and Integrity | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,799,008 | July 22, 2021 | May 31, 2027 | REN, HONGMEI | reporter.nih.gov |
| Controllable base editing therapy for DMD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,786,579 | September 1, 2023 | August 31, 2027 | HAN, RENZHI | reporter.nih.gov |
| Ferroptosis in the Heart: Iron Calcium Crosstalk and Compartmentalization | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,751,600 | December 25, 2021 | November 30, 2026 | XIE, LAI-HUA | reporter.nih.gov |
| REGULATION OF SKELETAL MUSCLE DEVELOPMENT AND MAINTENANCE BY PROTEIN O-GLUCOSYLTRANSFERASE 1 (POGLUT1) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,740,283 | July 8, 2020 | June 30, 2025 | JAFAR-NEJAD, HAMED | reporter.nih.gov |
| Therapeutic genetics and disease modeling in LAMA2-CMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,737,152 | July 1, 2022 | May 31, 2027 | VOCKLEY, GERARD | reporter.nih.gov |
| Mechanisms of mineralocorticoid receptor antagonism on inflammation in muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,726,538 | January 1, 2022 | December 31, 2026 | RAFAEL-FORTNEY, JILL A | reporter.nih.gov |
| Mechanisms of sodium channel clustering at the neuromuscular junction | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,723,360 | January 20, 2020 | December 31, 2029 | RASBAND, MATTHEW N | reporter.nih.gov |
| Investigating the direct reprogramming of fibroblasts into skeletal muscle progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,713,632 | August 15, 2020 | May 31, 2025 | HOCHEDLINGER, KONRAD | reporter.nih.gov |
| Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,694,079 | September 23, 2023 | August 31, 2027 | WEISLEDER, NOAH | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $1,672,364 | February 15, 2016 | August 31, 2022 | HOFFMAN, ERIC P. | reporter.nih.gov |
| Functions of skeletal muscle mineralocorticoid receptor signaling in chronic and acute injury | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,666,931 | April 1, 2018 | August 31, 2029 | RAFAEL-FORTNEY, JILL A | reporter.nih.gov |
| Mechanism and Function Of MBNL Mediated mRNA Localization in Neuronal Development and Neurologic Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,653,327 | February 1, 2020 | January 31, 2026 | BASSELL, GARY J | reporter.nih.gov |
| 3D Bioprinted Human Model of Duchenne Muscular Dystrophy (DMD) Cardiomyopathy to Study Disease Progression with Imposed Force and Precise Gene Editing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,651,448 | July 1, 2023 | April 30, 2028 | KAMDAR, FORUM D | reporter.nih.gov |
| CRISPR editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,639,600 | July 15, 2023 | June 30, 2028 | DUAN, DONGSHENG | reporter.nih.gov |
| Replication through DNA Structures and Consequences for Genome Stability | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,623,623 | January 1, 2022 | December 31, 2026 | FREUDENREICH, CATHERINE H | reporter.nih.gov |
| Biomarker Signatures for Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,617,513 | April 1, 2022 | March 31, 2026 | HATHOUT, YETRIB | reporter.nih.gov |
| Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,583,772 | February 10, 2023 | November 30, 2027 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,576,689 | January 23, 2024 | December 31, 2028 | SOSLOW, JONATHAN HARVEY | reporter.nih.gov |
| Dynamic Biomaterial Design to Probe the Cellular Response to Fibrotic Stiffening | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,574,063 | August 15, 2021 | July 31, 2025 | BLAU, HELEN M | reporter.nih.gov |
| Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,559,533 | September 25, 2023 | July 31, 2027 | KYBA, MICHAEL | reporter.nih.gov |
| LIM domain kinases: regulation and substrate recognition | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,534,536 | September 1, 2022 | August 31, 2026 | BOGGON, TITUS JONATHON | reporter.nih.gov |
| Decipher Mechano-Chemo-Transduction Pathway and Function in Cardiomyocytes | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,526,146 | September 1, 2021 | February 28, 2023 | CHEN-IZU, YE | reporter.nih.gov |
| Development of novel genetic medicine approaches to treat orphan diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,517,370 | September 19, 2024 | May 31, 2026 | CHILDERS, MARTIN K | reporter.nih.gov |
| Development of early metabolic imaging biomarkers for muscular dystrophy and cardiomyopathy in patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,514,698 | June 15, 2024 | April 30, 2028 | PARK, JAE MO | reporter.nih.gov |
| Molecular mechanisms of telomere function in muscle stem cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,514,489 | April 1, 2020 | April 28, 2025 | MOURKIOTI, FOTEINI | reporter.nih.gov |
| Engineering a Human Skeletal Muscle Tissue Model of LGMD2B | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,508,754 | August 15, 2023 | July 31, 2028 | BURSAC, NENAD | reporter.nih.gov |
| Structure and Function in alpha-Dystroglycan Glycosylation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,494,481 | August 1, 2014 | January 31, 2027 | WELLS, LANCE | reporter.nih.gov |
| Nuclear mechanics and mechanotransduction in muscular laminopathies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,481,781 | January 1, 2007 | June 30, 2024 | LAMMERDING, JAN | reporter.nih.gov |
| Mapping the non-coding RNA landscape in skeletal muscle health and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,452,283 | April 17, 2023 | March 31, 2029 | COSGROVE, BENJAMIN DAVID | reporter.nih.gov |
| SMCHD1 Pathways as Candidate Targets for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $1,429,596 | April 25, 2014 | June 30, 2025 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,427,720 | September 10, 2019 | June 30, 2025 | MORIZANE, RYUJI | reporter.nih.gov |
| CNS in Congenital DM1: Pathogenesis and Therapeutic Opportunities | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,422,143 | February 1, 2020 | January 31, 2026 | TIMCHENKO, LUBOV T | reporter.nih.gov |
| Structural Mechanisms Of Genome Flow In Bacteriophage T4 And Their Biomedical Applications | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,410,926 | February 15, 2023 | January 31, 2028 | RAO, VENIGALLA B. | reporter.nih.gov |
| Understanding the Mechanisms of Fibrosis in Muscular Dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,392,499 | July 12, 2023 | May 31, 2028 | HAMMERS, DAVID W | reporter.nih.gov |
| Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,392,382 | July 15, 2024 | May 31, 2028 | FRAIDENRAICH, DIEGO | reporter.nih.gov |
| Pathogenesis of Emery-Dreifuss Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,385,343 | May 15, 2003 | June 30, 2026 | WORMAN, HOWARD J | reporter.nih.gov |
| IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients | NIH | National Heart, Lung, and Blood Institute | 2024 | $1,358,179 | September 20, 2024 | September 19, 2025 | STRANGE, KEVIN | reporter.nih.gov |
| The role of nuclear envelope protein NET39 in skeletal muscle function and diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,346,145 | April 1, 2023 | January 31, 2028 | OLSON, ERIC N | reporter.nih.gov |
| Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,340,252 | January 18, 2023 | December 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| Ciliary Hedgehog signaling during adult tissue repair and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,327,925 | April 1, 2022 | March 31, 2027 | KOPINKE, DANIEL | reporter.nih.gov |
| Targeting Nitrate-Nitrite-NO pathway for Ameliorating Muscle and Bone Comorbidities in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,321,811 | September 15, 2020 | August 31, 2025 | LI, HONGSHUAI | reporter.nih.gov |
| Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,321,604 | August 1, 2019 | April 30, 2027 | YOUNG, COURTNEY S | reporter.nih.gov |
| To explore the molecular and cellular effects of transient DUX4 expression in skeletal muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,319,670 | September 1, 2022 | June 30, 2027 | BOSNAKOVSKI, DARKO | reporter.nih.gov |
| Small molecule therapeutics for myotonic dystrophy type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,293,169 | January 15, 2023 | December 31, 2027 | COMAI, LUCIO | reporter.nih.gov |
| A novel agent for preventing fatty degeneration of muscles in LGMD2B | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $1,292,847 | July 1, 2025 | June 30, 2027 | FLOER, MONIQUE | reporter.nih.gov |
| Optimizing Gene Therapy for Respiratory Insufficiency in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,258,938 | July 29, 2024 | June 30, 2028 | ELMALLAH, MAI | reporter.nih.gov |
| Defining nuclear mechanisms for ultrarapid mechanically induced gene expression | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,222,648 | September 1, 2024 | August 31, 2029 | LAMMERDING, JAN | reporter.nih.gov |
| Mechanism of Mitochondria-induced Progressive Muscle Wasting | NIH | National Institute on Aging | 2021 to 2023 | $1,190,088 | January 1, 2019 | November 30, 2025 | CHEN, XIN JIE | reporter.nih.gov |
| Developing DWORF gene therapy to treat heart failure and muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,187,696 | December 11, 2023 | November 30, 2027 | MAKAREWICH, CATHERINE A | reporter.nih.gov |
| Cellular protein maturation and degradation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,154,706 | April 1, 1999 | October 31, 2025 | RAUCH, JENNIFER NICOLE | reporter.nih.gov |
| Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,153,657 | January 12, 2024 | December 31, 2028 | ROGERS, RUSSELL | reporter.nih.gov |
| Modulation of Jagged1/Pitpna in DMD as a means of therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,152,624 | April 1, 2014 | July 31, 2025 | KUNKEL, LOUIS M | reporter.nih.gov |
| Development and Application of Muscle Diffusion Tensor MRI | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $1,147,425 | May 7, 2019 | December 31, 2025 | DAMON, BRUCE M. | reporter.nih.gov |
| Role of FGF21 in DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,142,423 | August 7, 2024 | June 30, 2029 | LI, HONGSHUAI | reporter.nih.gov |
| Impeding transcription of expanded microsatellite repeats using deactivated Cas9 | NIH | National Institute on Aging | 2021 to 2023 | $1,133,433 | February 15, 2019 | December 31, 2023 | WANG, ERIC T | reporter.nih.gov |
| Myo10-Driven Filopodia in Skeletal Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,112,948 | July 1, 2019 | May 31, 2025 | SWEENEY, H LEE | reporter.nih.gov |
| Multi-coil multi-nuclear add-on system for clinical field strength NMR-based biomarker detection for Duchenne Muscular Dystrophy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,110,294 | April 1, 2020 | December 31, 2024 | MCDOUGALL, MARY PRESTON | reporter.nih.gov |
| Single and Double AAV Somatic Gene Amelioration of Mouse Models of LAMA2 Related Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $1,091,199 | August 7, 2025 | July 31, 2028 | YURCHENCO, PETER DANA | reporter.nih.gov |
| Comprehensive gene and DNA variant curation for neuromuscular diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,079,672 | June 15, 2021 | May 31, 2025 | ZUCHNER, STEPHAN | reporter.nih.gov |
| Modulating the adaptive immune response to enhance the efficiency of in vivo gene editing in muscle | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,074,756 | July 1, 2024 | June 30, 2029 | SERWOLD, THOMAS F | reporter.nih.gov |
| Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,068,101 | May 1, 2024 | March 31, 2028 | MONTES, JACQUELINE | reporter.nih.gov |
| DISEASE MODELING AND PHENOTYPIC DRUG SCREENING FOR DYSTROPHIC CARDIOMYOPATHY | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,063,408 | May 15, 2020 | April 30, 2024 | KIM, DEOK-HO | reporter.nih.gov |
| C2 domain therapeutics for muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,060,272 | July 30, 2024 | June 30, 2029 | BLOCH, ROBERT J | reporter.nih.gov |
| Smad8 is a driver of Duchenne muscular dystrophy pathology via myomiR repression | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,050,867 | December 1, 2020 | November 30, 2026 | LOPEZ, MICHAEL ALONZO | reporter.nih.gov |
| Allele Specific Knockdown for LGMDD1 | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,047,312 | March 21, 2024 | February 28, 2029 | FINDLAY, ANDREW | reporter.nih.gov |
| Massively-parallel functional interrogation of genetic variation in CMD-associated alpha-dystroglycan glycosylating enzymes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,039,693 | September 26, 2023 | June 30, 2028 | HALLER, GABRIEL E | reporter.nih.gov |
| Mechanisms of DUX4-induced misregulation of RNA processing and quality control | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,028,342 | August 1, 2024 | May 31, 2029 | JAGANNATHAN, SUJATHA | reporter.nih.gov |
| In vivo role of the fibroblast in muscular dystrophy-Renewal | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $1,026,671 | April 1, 2018 | June 30, 2030 | VANHOUTTE, DAVY | reporter.nih.gov |
| Developing co-stimulatory blockade as a therapeutic strategy for Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,023,750 | September 15, 2019 | June 30, 2025 | TIDBALL, JAMES G | reporter.nih.gov |
| Structure-Function Analysis of Sarcospan | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $1,015,872 | September 24, 2001 | May 31, 2025 | CROSBIE, RACHELLE HOPE | reporter.nih.gov |
| Technologies to enable safe and effective gene editing in skeletal muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,011,048 | September 10, 2024 | July 31, 2029 | WANG, ERIC T | reporter.nih.gov |
| ANO5 in Muscle Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,000,584 | April 1, 2019 | December 31, 2022 | HAN, RENZHI | reporter.nih.gov |
| Development and optimization of skeletal muscle delivery vehicles | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $997,591 | July 8, 2024 | May 31, 2029 | MILLAY, DOUGLAS PAUL | reporter.nih.gov |
| Targeting PTEN to ameliorate muscular dystrophy in a mouse model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $989,224 | January 27, 2022 | December 31, 2024 | KUANG, SHIHUAN | reporter.nih.gov |
| Mechanisms of corticosteroids in dystrophic cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $968,546 | August 1, 2020 | November 1, 2023 | HEIER, CHRISTOPHER RYAN | reporter.nih.gov |
| Mechanisms of NAD+ action during muscle development and homeostasis in a zebrafish dystroglycanopathy model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $950,752 | August 2, 2019 | July 31, 2025 | HENRY, CLARISSA A | reporter.nih.gov |
| The mechanisms and functions of nuclear spacing in muscle development | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $939,000 | August 1, 2023 | July 31, 2027 | FOLKER, ERIC S | reporter.nih.gov |
| Origins and Functions of Intramuscular Macrophages in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $935,104 | August 5, 2019 | February 29, 2024 | ZHOU, LAN | reporter.nih.gov |
| Synaptic dysfunction in models of dystroglycanopathy | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $934,532 | April 1, 2024 | March 31, 2029 | WRIGHT, KEVIN | reporter.nih.gov |
| The Role of Dystrophin in Synapse Development | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $927,492 | August 2, 2024 | July 31, 2029 | PUGH, JASON RICHARD | reporter.nih.gov |
| GSK3 beta study in patients with Myotonic Dystrophy 1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $916,916 | January 15, 2019 | December 31, 2024 | TIMCHENKO, LUBOV T | reporter.nih.gov |
| Copolymer-Based Sarcolemma Stabilization for Protecting Dystrophic Skeletal Muscles in Vivo | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $914,016 | May 1, 2018 | April 30, 2024 | METZGER, JOSEPH MARK | reporter.nih.gov |
| Clinical and Translational studies in muscle disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $903,972 | July 1, 2018 | June 30, 2028 | WEIHL, CONRAD C | reporter.nih.gov |
| Pathogenic mechanisms and therapeutics for the cardiac manifestations of myotonic dystrophy type 1 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $863,194 | April 15, 2019 | March 31, 2025 | COOPER, THOMAS A | reporter.nih.gov |
| Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $850,142 | July 1, 2022 | June 30, 2027 | PUWANANT, ARAYA | reporter.nih.gov |
| Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $840,961 | September 1, 2023 | August 31, 2025 | ODOM, GUY LEARY | reporter.nih.gov |
| Pharmacodynamic Biomarker of Myotonic Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $822,772 | August 1, 2023 | May 31, 2028 | THORNTON, CHARLES A | reporter.nih.gov |
| Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2021 | $807,541 | September 1, 2020 | July 31, 2022 | KIM, DEOK-HO | reporter.nih.gov |
| Molecular basis of telomere dysfunction in cardiac dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $802,230 | August 1, 2019 | June 30, 2024 | MOURKIOTI, FOTEINI | reporter.nih.gov |
| Sarcoglycan in Myopathy and Muscle Membrane Stability | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $790,000 | July 1, 1999 | January 31, 2025 | MCNALLY, ELIZABETH M | reporter.nih.gov |
| Laminin protein therapy for the treatment of Laminin-alpha2 deficient congenital muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $778,704 | April 1, 2024 | March 31, 2029 | BURKIN, DEAN J. | reporter.nih.gov |
| Electrical impedance myography in an animal model | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $766,280 | August 1, 2007 | July 31, 2024 | RUTKOVE, SEWARD B. | reporter.nih.gov |
| Mechanisms of corticosteroids in dystrophic cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $758,329 | August 1, 2020 | July 31, 2025 | HEIER, CHRISTOPHER RYAN | reporter.nih.gov |
| RNA Toxicity and Cardiac Pathology | NIH | National Heart, Lung, and Blood Institute | 2022 | $754,977 | September 21, 2022 | August 31, 2024 | MAHADEVAN, MANI SUBRAMANIAM | reporter.nih.gov |
| Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy | NIH | Office of the Director, National Institutes of Health | 2021 | $752,426 | April 1, 2015 | August 31, 2023 | BURKIN, DEAN J. | reporter.nih.gov |
| Dynamic interplay of eukaryotic translation and mRNA decay | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $747,000 | April 1, 2022 | August 31, 2026 | LAWSON, MICHAEL R | reporter.nih.gov |
| Targeting Pannexin 1 as a Novel Mechanism for Arrhythmia and Fibrosis in Duchenne Cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $741,945 | January 7, 2021 | December 31, 2025 | RAUCCI, FRANK J | reporter.nih.gov |
| Spatial Regulators of Skeletal Muscle Regeneration and Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $738,702 | September 30, 2020 | February 28, 2026 | WANG, YU XIN | reporter.nih.gov |
| Engineering Mesenchymal Stromal Cells to treat Muscle Fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $716,759 | September 1, 2023 | June 30, 2027 | WONG, SING-WAN | reporter.nih.gov |
| Basement membrane self-assembly and structure | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $715,500 | January 1, 1986 | June 30, 2024 | YURCHENCO, PETER DANA | reporter.nih.gov |
| D4Z4 Coding Transcripts and FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $696,022 | September 1, 1998 | March 31, 2022 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| Understanding regulation of pediatric regenerative myogenesis and its implication for muscle disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $692,292 | April 1, 2025 | March 31, 2030 | NOVAK, JAMES STEPHEN | reporter.nih.gov |
| Expression of dystrophins with enhanced function | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $671,240 | January 22, 2025 | December 31, 2029 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Molecular regulation of muscle development by Smyd1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $669,603 | September 7, 2018 | July 31, 2025 | DU, SHAOJUN | reporter.nih.gov |
| The role of TGF beta pathway dysregulation in pathogenesis of collagen VI-related muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $666,024 | July 1, 2017 | June 30, 2025 | MOHASSEL, PAYAM | reporter.nih.gov |
| Noninvasive Phenotyping of Respiratory Function in People with Muscular Dystrophies Using Electrical Impedance Tomography | NIH | National Heart, Lung, and Blood Institute | 2025 | $655,885 | September 15, 2025 | June 30, 2030 | MUELLER, JENNIFER LYNN | reporter.nih.gov |
| A MIR-486/DOCK3 SIGNALING AXIS MODULATES DYSTROPHIN-DEFICIENT PATHOLOGY | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $653,868 | August 17, 2018 | May 31, 2024 | ALEXANDER, MATTHEW SCOTT | reporter.nih.gov |
| Extracellular RNA biomarkers of myotonic dystrophy type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $653,302 | June 15, 2021 | May 31, 2027 | WHEELER, THURMAN M | reporter.nih.gov |
| Identification of Genetic and Molecular Pathways in Congenital Rare Disorders Affecting the Brain and Muscle | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $653,240 | August 15, 2019 | January 31, 2025 | MANZINI, M. CHIARA | reporter.nih.gov |
| HTS to identify compounds that increase NAD+ levels in neurons and muscle cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $652,611 | June 1, 2022 | May 31, 2025 | KHURANA, TEJVIR S | reporter.nih.gov |
| Readthrough of disease-causing nonsense mutations by targeted selenocysteine recoding | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $644,779 | September 20, 2022 | August 31, 2025 | REGEV, ODED | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $616,017 | June 16, 2022 | May 31, 2027 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Ferroptosis in the Heart: Iron Calcium Crosstalk and Compartmentalization | NIH | National Heart, Lung, and Blood Institute | 2022 | $603,528 | December 25, 2021 | November 30, 2022 | XIE, LAI-HUA | reporter.nih.gov |
| Clinical and Non-Invasive Biomarkers of Myotonic Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $602,640 | December 15, 2022 | November 30, 2027 | GONZALEZ-PEREZ, PALOMA | reporter.nih.gov |
| Deciphering the roles of FXR1 in health and myopathy | NIH | National Heart, Lung, and Blood Institute | 2022 | $601,489 | August 1, 2022 | April 30, 2023 | GREGORIO, CAROL C | reporter.nih.gov |
| MR Assessment of the effect of nNOS on Bioenergetics and Microvascular Function in Becker and Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $599,496 | September 15, 2025 | August 31, 2030 | FORBES, SEAN C | reporter.nih.gov |
| Whole body single AAV microgene in canine DMD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $598,651 | September 1, 2015 | April 30, 2030 | DUAN, DONGSHENG | reporter.nih.gov |
| Beckman Coulter Biomek i7 Hybrid automated workstation | NIH | Office of the Director, National Institutes of Health | 2024 | $594,187 | April 1, 2024 | March 31, 2025 | HUANG, CHUN-TENG | reporter.nih.gov |
| Molecular Mechanisms of Dystrophic Cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $568,465 | August 1, 2019 | May 31, 2024 | WANG, DA-ZHI | reporter.nih.gov |
| Biophysical Studies of Caveolin | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $544,990 | July 1, 2021 | June 30, 2025 | GLOVER, KERNEY JEBRELL | reporter.nih.gov |
| The role Akirin and Pannier interactions during myogenesis | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $542,000 | April 15, 2022 | March 31, 2027 | NOWAK, SCOTT JAMES | reporter.nih.gov |
| Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $536,800 | September 15, 2023 | August 31, 2026 | TAIVASSALO, TANJA | reporter.nih.gov |
| Preclinical development of DMD exon 44 skipping using AAV.U7snRNA: a versatile tool that can help 6-12% of DMD patient | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $519,166 | August 8, 2025 | January 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| MOLECULAR MECHANISMS OF DYSTROPHIC CARDIOMYOPATHY | NIH | National Heart, Lung, and Blood Institute | 2021 | $518,390 | August 1, 2019 | August 30, 2021 | WANG, DA-ZHI | reporter.nih.gov |
| Assembly of the Dystrophin-Glycoprotein Complex | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $508,614 | April 19, 1997 | March 31, 2022 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $499,954 | April 1, 2016 | March 31, 2023 | TANG, YAO LIANG | reporter.nih.gov |
| Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $499,300 | September 1, 2025 | July 31, 2028 | YOUNG, COURTNEY S | reporter.nih.gov |
| Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $499,207 | August 1, 2019 | March 31, 2023 | YOUNG, COURTNEY S | reporter.nih.gov |
| TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $498,000 | March 18, 2024 | February 28, 2027 | LIN, BRIAN LEEI | reporter.nih.gov |
| Modulating Fibro/Adipogenic Precursors to Prevent Adipogenic Replacement of Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $496,710 | May 21, 2021 | April 30, 2026 | HOGARTH, MARSHALL | reporter.nih.gov |
| Physiologic stress in advanced tissue culture models of cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $492,156 | December 15, 2022 | November 30, 2027 | FULLENKAMP, DOMINIC EDWARD | reporter.nih.gov |
| Investigating membrane repair capacity in facioscapulohumeral muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $490,875 | March 6, 2021 | February 29, 2024 | CHEN, YI-WEN | reporter.nih.gov |
| Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD) | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $490,761 | August 18, 2023 | July 31, 2026 | KHURANA, TEJVIR S | reporter.nih.gov |
| Mitochondrial Regulation of Calcium Homeostasis and Cell Death in Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $490,531 | March 4, 2024 | April 30, 2027 | BROUND, MICHAEL | reporter.nih.gov |
| Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $487,764 | November 1, 2023 | October 31, 2026 | WEN, YUAN | reporter.nih.gov |
| Gene Therapy Design Principles for Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $476,731 | September 1, 2023 | August 31, 2028 | EGUCHI, ASUKA | reporter.nih.gov |
| Emerin regulation of myogenic differentiation: implications for muscle disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $475,680 | April 1, 2016 | June 30, 2026 | HOLASKA, JAMES MICHAEL | reporter.nih.gov |
| Tissue-specific roles for muscle-matrix adhesion in neuromuscular development and homeostasis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $471,513 | September 5, 2025 | August 31, 2030 | HENRY, CLARISSA A | reporter.nih.gov |
| Microtubule Regulated Mechanotransduction in Skeletal Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $466,851 | September 21, 2017 | July 31, 2023 | WARD, CHRISTOPHER WILLIAM | reporter.nih.gov |
| Progressive loading of a human dystrophic cardiomyopathy 3D model to mimic disease and evaluate therapeutic | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $465,872 | September 1, 2022 | August 31, 2025 | KAMDAR, FORUM D | reporter.nih.gov |
| PAR-18-953 (ASCOT-DMD) | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $456,600 | August 15, 2021 | May 31, 2025 | THANGARAJH, MATHULA | reporter.nih.gov |
| Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $453,073 | May 13, 2022 | May 31, 2023 | TAWIL, RABI | reporter.nih.gov |
| Longitudinal Assessment of Molecular and Imaging Biomarkers in LGMDR1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $448,278 | September 18, 2025 | July 31, 2029 | HEIER, CHRISTOPHER RYAN | reporter.nih.gov |
| CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor) | NIH | National Heart, Lung, and Blood Institute | 2025 | $444,838 | September 4, 2025 | August 31, 2027 | MARKHAM, LARRY W. | reporter.nih.gov |
| Characterizing Tissue Specific Regulation of Mutant Lamin Protein Degradation | NIH | National Institute on Aging | 2021 | $442,936 | July 1, 2016 | August 30, 2025 | HAMMOND, THOMAS MICHAEL | reporter.nih.gov |
| Development of myotropic human bocavirus vectors for gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $440,675 | June 12, 2024 | April 30, 2027 | QIU, JIANMING | reporter.nih.gov |
| Development of anti-LTBP4 as a biologic to treat Limb Girdle Muscular Dystrophy 2C | NIH | National Center for Advancing Translational Sciences | 2025 | $440,000 | August 1, 2025 | July 31, 2027 | DEMONBREUN, ALEXIS R. | reporter.nih.gov |
| Molecular Consequences of Myotonic Dystrophy Type 2-causing CCTG DNA Repeats | NIH | National Institute of General Medical Sciences | 2024 | $434,750 | August 1, 2024 | July 31, 2027 | KIM, JANE C | reporter.nih.gov |
| Structure-based antisense therapeutics targeting dystrophin exons 44 and 45 for Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $433,125 | September 1, 2024 | August 31, 2026 | GUO, FENG | reporter.nih.gov |
| Mechanisms of altered RNA transport dynamics by Kif1C mutations in heterospastic paraplegia | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $430,375 | July 1, 2025 | June 30, 2027 | BASSELL, GARY J | reporter.nih.gov |
| Clinical Trial Readiness for Monitoring Muscle Inflammation in Duchenne Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2023 to 2024 | $429,645 | August 1, 2023 | June 30, 2026 | HOFFMAN, ERIC P. | reporter.nih.gov |
| Brain Connectivity Signatures of Behavior and Cognition in Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $429,000 | September 30, 2021 | March 31, 2025 | JOSHI, SHANTANU H. | reporter.nih.gov |
| The Role of DNAJB6 in Muscle and the Impact of LGMD1D Mutations | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $417,402 | August 1, 2019 | July 31, 2024 | FINDLAY, ANDREW | reporter.nih.gov |
| Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $414,187 | September 1, 2021 | July 31, 2024 | KIM, SARAH | reporter.nih.gov |
| Foundations for a Phase 1 Clinical Trial ofCell-based Therapy for Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $409,200 | July 15, 2022 | June 30, 2024 | KANG, PETER B. | reporter.nih.gov |
| NADPH Oxidase and Autophagic Dysfunction in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $409,087 | August 1, 2012 | July 31, 2023 | RODNEY, GEORGE G | reporter.nih.gov |
| Therapeutic targeting of miR-128-1 in Duchenne muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $401,250 | August 1, 2022 | July 31, 2024 | NAAR, ANDERS M | reporter.nih.gov |
| Development of MRI, Alternative Splicing, and Functional Abilities asBiomarkers in Myotonic Dystrophy Type 1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $401,093 | August 17, 2020 | June 30, 2024 | LOTT, DONOVAN J | reporter.nih.gov |
| Improving delivery of therapeutic material to skeletal muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $397,497 | September 20, 2019 | May 31, 2024 | MILLAY, DOUGLAS PAUL | reporter.nih.gov |
| Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $395,224 | July 15, 2021 | June 30, 2024 | HARPER, SCOTT Q | reporter.nih.gov |
| Regulating fibrosis and growth through latent TGFbeta binding proteins | NIH | National Heart, Lung, and Blood Institute | 2021 | $395,000 | April 1, 2018 | January 31, 2023 | MCNALLY, ELIZABETH M | reporter.nih.gov |
| Connexin 43: a new player in Duchenne muscular dystrophy associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 | $394,768 | September 1, 2018 | June 30, 2023 | FRAIDENRAICH, DIEGO | reporter.nih.gov |
| RNA Toxicity and Muscle Regeneration | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $385,227 | February 20, 2017 | December 31, 2021 | MAHADEVAN, MANI SUBRAMANIAM | reporter.nih.gov |
| Investigating proteostasis in facioscapulohumeral muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $382,644 | July 1, 2022 | May 31, 2025 | CHEN, YI-WEN | reporter.nih.gov |
| Internal and External Validation of a Porcine Dystrophinopathy Model | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $382,500 | September 1, 2021 | August 31, 2023 | SELSBY, JOSHUA T | reporter.nih.gov |
| Identification of components and mechanisms regulating expanded CUG-repeat RNP complexes in Myotonic Dystrophy Type 1 muscle cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $381,920 | April 1, 2023 | March 31, 2026 | COOPER, THOMAS A | reporter.nih.gov |
| Elucidation of the role of human genetic factors underlying viral myocarditis susceptibility | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $380,676 | July 6, 2018 | June 30, 2023 | KONTOROVICH, AMY R. | reporter.nih.gov |
| Functional and mechanistic analysis of FSHD myocytes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $379,940 | September 22, 2021 | August 31, 2024 | YOKOMORI, KYOKO | reporter.nih.gov |
| Massively-parallel functional interrogation of genetic variation in LGMD-associated sarcoglycan genes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $379,418 | July 1, 2021 | June 30, 2023 | HALLER, GABRIEL E | reporter.nih.gov |
| Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $378,792 | March 1, 2017 | January 31, 2024 | ZIMMERMAN, STEVEN C. | reporter.nih.gov |
| Ex vivo expansion of skeletal muscle satellite cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $378,232 | February 10, 2022 | December 31, 2024 | CORNELISON, DAWN D | reporter.nih.gov |
| Development of optimized AAVrh74 vectors for gene therapy of muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $377,143 | January 25, 2023 | December 31, 2025 | SRIVASTAVA, ARUN | reporter.nih.gov |
| Genetic repair of muscular degeneration associated with Duchenne muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $375,393 | June 1, 2016 | August 31, 2025 | VIDAL GADEA, ANDRES GABRIEL | reporter.nih.gov |
| Disease Modeling of Skeletaland Cardiac Muscle in DMD/BMD using Patient-Specific iPS Cells | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $375,100 | March 7, 2022 | February 29, 2024 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Systemic delivery of muscle stem cell for muscle disease therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $375,100 | May 1, 2022 | April 30, 2024 | ASAKURA, ATSUSHI | reporter.nih.gov |
| Targeting vascular endothelium for muscular dystrophy therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $373,065 | April 1, 2021 | March 31, 2024 | ASAKURA, ATSUSHI | reporter.nih.gov |
| N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $372,350 | March 6, 2023 | August 31, 2026 | DEY, BIJAN K | reporter.nih.gov |
| Understanding the mechanism and role of cell membrane repair in Miyoshi Myopathy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $371,128 | July 2, 2008 | June 30, 2024 | JAISWAL, JYOTI K | reporter.nih.gov |
| Micro-laminin Gene Therapy for MDC1A | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $370,986 | April 15, 2021 | March 31, 2024 | MARTIN, PAUL TAYLOR | reporter.nih.gov |
| Therapeutic Modulation of Myotonic Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $370,563 | September 1, 2015 | June 30, 2022 | THORNTON, CHARLES A | reporter.nih.gov |
| Innate Immune Activation in Autoimmune Myopathy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $368,836 | April 10, 2017 | March 31, 2023 | ASCHERMAN, DANA P | reporter.nih.gov |
| Mechanistic and Translational Investigations of HSPB8-associated dominant rimmed vacuolar myopathy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $368,764 | September 20, 2024 | August 31, 2026 | KIMONIS, VIRGINIA EUNICE | reporter.nih.gov |
| Accessible FSHD diagnostics through epigenetic analysis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $365,902 | February 1, 2022 | January 31, 2025 | JONES, PETER L | reporter.nih.gov |
| Opto-Electrophysiological Method to Study Human Skeletal Muscle Channelopathies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $360,360 | April 1, 2022 | January 31, 2025 | DI FRANCO, MARINO | reporter.nih.gov |
| DAPC structural adaption in regulating nanotopography-responsive myotube orientation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $354,222 | September 20, 2023 | August 31, 2025 | SHEN, WEI | reporter.nih.gov |
| Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $353,874 | May 10, 2017 | March 31, 2022 | PERLINGEIRO, RITA C. R. | reporter.nih.gov |
| Mechanisms and regulation of emerin self-assembly at the nuclear envelope: Implication for Emery-Dreifuss Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $352,750 | August 10, 2025 | July 31, 2030 | PINAUD, FABIEN | reporter.nih.gov |
| Interrogating functional and molecular properties of PAX7+ putative skeletal muscle stem/progenitor cells derived from human iPSCs of healthy donors and Duchenne muscular dystrophy patients | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $348,502 | March 1, 2017 | February 28, 2022 | LEE, GABSANG | reporter.nih.gov |
| Integrating multiomic analyses for gene discovery andgenetic diagnosis of Mendelian myopathies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $347,760 | February 16, 2024 | January 31, 2029 | GANESH, VIJAY S | reporter.nih.gov |
| PKR as a therapeutic target for muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $347,447 | July 29, 2022 | June 30, 2025 | SELSBY, JOSHUA T | reporter.nih.gov |
| Myokine function of MG53 in muscle injury-repair and regeneration | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $342,103 | April 15, 2017 | March 31, 2023 | HAN, RENZHI | reporter.nih.gov |
| Bioengineering of phage-derived particles as a discovery platform for muscle gene therapy | NIH | National Center for Advancing Translational Sciences | 2023 | $334,571 | September 1, 2023 | August 31, 2024 | TSEDEV, UYANGA | reporter.nih.gov |
| Computational prediction of RNA splicing defects and rescue by small-molecule therapeutics | NIH | National Institute of General Medical Sciences | 2023 | $333,843 | September 6, 2023 | December 31, 2023 | XIONG, HAISHAN | reporter.nih.gov |
| Muscle-Specific Basis of OPMD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $329,061 | September 1, 2011 | August 31, 2023 | CORBETT, ANITA H. | reporter.nih.gov |
| Identification of genetic and molecular pathways in congenital rare disorders affecting the brain and muscle | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $328,586 | August 15, 2019 | July 31, 2022 | MANZINI, M. CHIARA | reporter.nih.gov |
| Uncovering isoform-specific functions of RNA-binding protein Bruno1 in Drosophila muscle development | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $323,918 | September 15, 2025 | July 31, 2030 | SPLETTER, MARIA L | reporter.nih.gov |
| Application of RNA-targeting Cas9 to Fuchs' dystrophy | NIH | National Eye Institute | 2021 | $322,405 | April 1, 2018 | March 31, 2022 | YEO, EUGENE WEI-MING | reporter.nih.gov |
| AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $322,121 | July 18, 2023 | June 30, 2025 | HARPER, SCOTT Q | reporter.nih.gov |
| Targeting PTEN to ameliorate muscular dystrophy in a mouse model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $319,770 | January 27, 2022 | December 31, 2027 | KUANG, SHIHUAN | reporter.nih.gov |
| Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes | NIH | National Center for Advancing Translational Sciences | 2025 | $313,372 | August 7, 2025 | July 31, 2026 | CHEN, YI-WEN | reporter.nih.gov |
| In vivo imaging platform for DM1 drug discovery | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $313,148 | August 1, 2025 | July 31, 2026 | O'HANLON, RYAN | reporter.nih.gov |
| Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $311,250 | September 1, 2024 | August 31, 2026 | YOUNG, COURTNEY S | reporter.nih.gov |
| Functional mechanisms underlying Dystroglycan-dependent and independent roles of protein O-mannosylation in the nervous system | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $310,582 | July 1, 2017 | June 30, 2024 | PANIN, VLADISLAV M | reporter.nih.gov |
| Development of a Novel Calcium Channel Therapeutic for Dystrophinopathies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $306,872 | September 1, 2024 | July 31, 2025 | GREENBERG, MILTON L | reporter.nih.gov |
| Scalable Non-viral Gene Delivery for Neuromuscular Diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $306,859 | September 15, 2025 | August 31, 2026 | CHILDERS, MARTIN K | reporter.nih.gov |
| Ankle contractures in muscular dystrophy: mechanisms and tissue adaptations | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $305,000 | August 1, 2024 | July 31, 2026 | BARNARD, ALISON M | reporter.nih.gov |
| AI/ML and iPSC-Derived Organoids for Myotonic Dystrophy Drug Discovery | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $302,500 | June 1, 2024 | May 31, 2026 | PANG, PAUL | reporter.nih.gov |
| Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $302,500 | September 1, 2025 | August 31, 2027 | YOUNG, COURTNEY S | reporter.nih.gov |
| Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $299,591 | September 1, 2022 | August 31, 2024 | OZES, ALI RAYET | reporter.nih.gov |
| Delivery of Full Length Dystrophin to Muscle Cells for DMD Gene Therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $295,294 | September 1, 2023 | August 31, 2025 | JOHNSON, DAVID SCOTT | reporter.nih.gov |
| Curation of Muscular Dystrophy Genes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $290,137 | September 18, 2025 | August 31, 2028 | WEIHL, CONRAD C | reporter.nih.gov |
| A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | NIH | National Center for Advancing Translational Sciences | 2021 | $286,081 | September 17, 2021 | September 21, 2023 | LINKE, LYNDSEY | reporter.nih.gov |
| Translational development of novel CRISPR approach to treat genomic duplications | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $275,651 | August 1, 2023 | July 31, 2025 | LEK, MONKOL | reporter.nih.gov |
| Development of optimized adeno-associated viral capsids for muscle gene therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $274,152 | August 2, 2023 | July 31, 2025 | RODGERS, BUEL | reporter.nih.gov |
| Precise Length and 5-Methylcytosine Assessments of Repeat Sequences | NIH | National Human Genome Research Institute | 2021 | $271,933 | May 10, 2021 | April 30, 2023 | SCHIBEL, ANNA | reporter.nih.gov |
| Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $271,230 | July 13, 2020 | June 30, 2025 | CLEMENS, PAULA R | reporter.nih.gov |
| SMCHD1 Pathways as Candidate Targets for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $261,057 | April 25, 2014 | March 31, 2022 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| TRPC6 inhibition therapy to rescue cardiac muscle dysfunction in muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $260,660 | January 1, 2022 | December 31, 2023 | LIN, BRIAN LEEI | reporter.nih.gov |
| Translational development of recombinant protein therapeutic for LGMD2B | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $259,487 | August 1, 2022 | April 30, 2024 | WEISLEDER, NOAH | reporter.nih.gov |
| A Musculoskeletal Simulation Framework for In Silico Design and Optimization of a Soft Exosuit for Children with Muscular Dystrophy | NIH | National Center for Advancing Translational Sciences | 2021 | $253,606 | July 15, 2021 | July 14, 2022 | PICKLE, NATHANIEL | reporter.nih.gov |
| A novel agent for preventing fatty degeneration of muscles in LGMD2B | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $250,011 | September 7, 2022 | August 31, 2024 | FLOER, MONIQUE | reporter.nih.gov |
| Microtubule acetylation is a novel target in Duchenne muscular dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $245,862 | June 10, 2021 | May 31, 2023 | CAVALCANTE JOCA, HUMBERTO | reporter.nih.gov |
| Caspase-mediated nuclear pore complex trimming in myogenesis and muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $237,501 | February 1, 2023 | November 30, 2025 | CHO, UKRAE | reporter.nih.gov |
| Dystrophin as a novel regulator of the circadian clock in skeletal muscle and the brain | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $236,566 | December 23, 2024 | November 30, 2026 | ALEXANDER, MATTHEW SCOTT | reporter.nih.gov |
| Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $233,940 | August 17, 2022 | October 31, 2023 | WEN, YUAN | reporter.nih.gov |
| Myopathy in purine metabolic disorders: a model for adenylosuccinate synthase deficiency | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $233,494 | April 4, 2025 | March 31, 2027 | HANNA-ROSE, WENDY | reporter.nih.gov |
| STARFISH PIER: Study of Testosterone and rHGH in FSHD: Planning Infrastructure Execution and Readiness | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $203,280 | February 5, 2024 | April 30, 2025 | HEATWOLE, CHAD RYDEL | reporter.nih.gov |
| Development and validation of clinical outcome assessments in LGMD2A | NIH | National Center for Advancing Translational Sciences | 2021 | $198,181 | April 15, 2020 | April 30, 2024 | JOHNSON, NICHOLAS ELWOOD | reporter.nih.gov |
| Engineering mesenchymal stromal cells to treat muscle fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $197,478 | July 1, 2021 | August 15, 2022 | WONG, SING-WAN | reporter.nih.gov |
| Exploration of developmental brain abnormalities in mouse models of Duchenne muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $181,810 | March 3, 2021 | March 2, 2025 | ARREGUIN, ANDREA JASMINE | reporter.nih.gov |
| Mitochondrial regulation of calcium homeostasis and cell death in muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $181,440 | September 1, 2021 | May 31, 2024 | BROUND, MICHAEL | reporter.nih.gov |
| Nanoscale organization and mechanotransduction of emerin at the nuclear envelope: Implication for Emery-Dreifuss Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $176,055 | January 1, 2020 | June 30, 2022 | PINAUD, FABIEN | reporter.nih.gov |
| The Role of Alternative Splicing in FSHD Disease Models | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $175,500 | September 1, 2025 | July 31, 2030 | KNOX, RENATTA | reporter.nih.gov |
| A Novel Technology for Full-Length Gene Replacement Therapy of Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $167,855 | February 1, 2022 | June 11, 2025 | HSU, RYAN HON HEAN | reporter.nih.gov |
| Smad signaling in skeletal muscle laminopathies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $164,851 | March 1, 2020 | February 28, 2023 | WALLRATH, LORI L | reporter.nih.gov |
| Allele Specific Knockdown for LGMD-D1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $157,457 | July 15, 2022 | June 30, 2024 | FINDLAY, ANDREW | reporter.nih.gov |
| The mechanism of CELF1 upregulation and its role in the pathogenesis of Myotonic Dystrophy Type 1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $155,016 | January 1, 2024 | December 31, 2026 | NITSCHKE, LARISSA | reporter.nih.gov |
| Understanding the Transcriptional Networks and Physiologic Adaptations Governing the Clinical Manifestations of Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $152,942 | July 27, 2020 | July 26, 2024 | GARAY, BAYARDO ISIDORE | reporter.nih.gov |
| MBNL loss of function in visceral smooth muscle as a model of myotonic dystrophy type 1 | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $148,642 | December 15, 2022 | December 14, 2025 | PETERSON, JANEL ANN MERKEL | reporter.nih.gov |
| Altered nucleus-cytoskeleton coupling in dystrophic muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $148,067 | January 20, 2023 | March 31, 2025 | IYER, SHAMA RAJAN | reporter.nih.gov |
| Exploring the role of hypoxia signaling and its inhibition as a therapy for Facioscapulohumeral muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $143,574 | April 1, 2022 | March 31, 2024 | COHEN, JUSTIN | reporter.nih.gov |
| Dynamic interplay of eukaryotic translation and mRNA decay | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $131,224 | April 1, 2022 | June 30, 2023 | LAWSON, MICHAEL R | reporter.nih.gov |
| Caspase-mediated nuclear pore complex trimming in myogenesis and muscular dystrophies | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $130,976 | February 1, 2023 | December 31, 2023 | CHO, UKRAE | reporter.nih.gov |
| Spatiotemporal and Deep Learning Analysis of Cardiac Imaging for Predictive Risk Stratification in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $130,736 | August 5, 2022 | August 4, 2026 | EARL, CONNER | reporter.nih.gov |
| Understanding and regulating skeletal muscle progenitor and stem cell states through metabolic and epigenetic modulation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $126,024 | July 1, 2021 | June 30, 2024 | CHIEN, PEGGIE JANE | reporter.nih.gov |
| Consequence of human satellite repeat expression and immunostimulatory potential in FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $124,308 | September 15, 2025 | August 31, 2027 | ARENDS, TESSA AMANDA | reporter.nih.gov |
| Reactivation of an early embryonic program in FSHD and cancer | NIH | National Cancer Institute | 2022 to 2023 | $115,698 | December 1, 2020 | November 30, 2023 | HAMM, DANIELLE | reporter.nih.gov |
| Mechanisms of Myotonic Dystrophy Type 2-causing CCTG DNA Repeat Instability | NIH | National Institute of General Medical Sciences | 2021 | $111,750 | April 13, 2018 | March 31, 2023 | KIM, JANE C | reporter.nih.gov |
| Identification and characterization of factors affecting cytoskeletal proteins--the mediators of bacterial cell shape | NIH | National Institute of General Medical Sciences | 2021 | $108,750 | May 1, 2018 | April 30, 2023 | MURRAY, SEAN | reporter.nih.gov |
| Altered nucleus-cytoskeleton coupling in dystrophic muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $103,412 | July 5, 2019 | June 14, 2022 | IYER, SHAMA RAJAN | reporter.nih.gov |
| CRISPR therapy in the canine DMD model | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $99,608 | September 20, 2022 | August 31, 2023 | DUAN, DONGSHENG | reporter.nih.gov |
| Contribution of hydrogen sulfide to Duchenne muscular dystrophy pathophysiology | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $93,520 | August 1, 2024 | May 1, 2027 | FALLON, KATHERINE SAGE | reporter.nih.gov |
| Dystroglycan regulates cerebellar synapse function | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $92,788 | September 28, 2020 | September 27, 2023 | JAHNCKE, JENNIFER | reporter.nih.gov |
| Muscleblind facilitates kinesin dependent RNA localization in neurons | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $92,788 | September 21, 2020 | July 19, 2023 | KNUDSON, LUKE ANDREW | reporter.nih.gov |
| Spatiotemporal and Deep Learning Analysis of Cardiac Imaging for Predictive Risk Stratification in Duchenne Muscular Dystrophy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $89,498 | August 5, 2022 | March 31, 2024 | EARL, CONNER | reporter.nih.gov |
| A Long-read Sequencing Approach for Investigating Repeat Number and DNA Methylation of the D4Z4 Region | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $89,250 | February 1, 2020 | January 31, 2023 | CHEN, YI-WEN | reporter.nih.gov |
| Spatial Regulators of Skeletal Muscle Regeneration and Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $88,722 | September 30, 2020 | August 31, 2022 | WANG, YU XIN | reporter.nih.gov |
| Improving cell membrane repair to treat muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $84,694 | August 1, 2022 | July 31, 2024 | LOPEZ PEREZ, MIGUEL AARON | reporter.nih.gov |
| Uncovering the function of emerin and its regulation by secretory trafficking in human cardiomyocytes | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $83,550 | May 1, 2024 | April 30, 2026 | MELLA, JESSICA | reporter.nih.gov |
| Development of Muscle Optimized Non-viral Gene Editors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $75,520 | December 1, 2025 | November 30, 2028 | POUKALOV, KERIL | reporter.nih.gov |
| Abnormalities in postnatal brain development as a feature of congenital muscular dystrophies | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $71,238 | December 15, 2020 | December 14, 2021 | COLOGNATO, HOLLY A | reporter.nih.gov |
| Muscle-Specific CRISPR/Cas9 Exon Skipping for Duchenne Muscular Dystrophy Therapeutics | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $66,236 | September 1, 2023 | August 31, 2025 | KRAUS, CAROLYN | reporter.nih.gov |
| Alternative Splicing Regulation and Mechanotransduction in Skeletal Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $65,773 | April 1, 2021 | November 18, 2022 | HINKLE, EMMA | reporter.nih.gov |
| Identifying the interactions between fibro-adipogenic progenitors and the extracellular matrix in skeletal muscle fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $60,305 | August 1, 2023 | November 30, 2024 | LOOMIS, TARYN | reporter.nih.gov |
| Micropatterned surfaces for modeling muscular dystrophy-associated cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $56,082 | August 1, 2020 | March 31, 2022 | FULLENKAMP, DOMINIC EDWARD | reporter.nih.gov |
| Genetic and pharmacologic elimination of myotonia from myotonic dystrophy type 1 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $47,694 | August 1, 2023 | July 31, 2024 | SIPPLE, MATTHEW THOMAS | reporter.nih.gov |
| Investigating the role of FGF21 in bone homeostasis in Duchenne Muscular Dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $46,138 | May 1, 2025 | April 30, 2029 | HURLEY-NOVATNY, AMELIA CHARLOTTE | reporter.nih.gov |
| Implications of Epigenetic Regulation in Congenital Myotonic Dystrophy through Development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $45,988 | December 5, 2025 | December 4, 2029 | HARTMAN, JULIA MARIE | reporter.nih.gov |
| Role of Connexin43 in the heart and skeletal muscle in a model for Duchenne muscular dystrophy symptomatic carriers | NIH | National Heart, Lung, and Blood Institute | 2022 | $40,959 | September 1, 2020 | August 31, 2023 | NOUET, JULIE | reporter.nih.gov |
| Role of Connexin43 in the heart and skeletal muscle in a model for Duchenne muscular dystrophy symptomatic carriers | NIH | National Heart, Lung, and Blood Institute | 2021 | $40,243 | September 1, 2020 | August 31, 2022 | NOUET, JULIE | reporter.nih.gov |
| Exploring the link between mutant RNA expression and trinucleotide repeat disease | NIH | National Eye Institute | 2021 | $34,751 | May 1, 2019 | April 30, 2023 | JOHNSON, SAMANTHA TORI | reporter.nih.gov |
| Development of RNA-Directed Therapeutics for Myotonic Dystrophy Type 1 Neuropathology | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $34,281 | July 1, 2019 | December 31, 2021 | MORELLI, KATHRYN H | reporter.nih.gov |
| AQP4 Associations with Alzheimer's Disease: A Multi-omics Approach | NIH | National Institute on Aging | 2024 | $34,269 | July 5, 2024 | July 4, 2026 | PHILLIPS, JARED | reporter.nih.gov |
| Identifying tissue-specific interactions to bridge mechanisms underlying muscle degeneration in Congenital Disorders of Glycosylation and Dystroglycanopathies | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $34,007 | December 1, 2024 | November 30, 2026 | IGNACZ, AMANDA COLLEEN | reporter.nih.gov |
| Single-cell splicing analysis of the heart in myotonic dystrophy | NIH | National Heart, Lung, and Blood Institute | 2021 | $31,705 | August 12, 2020 | January 31, 2022 | PANG, PAUL | reporter.nih.gov |
| Using collagenase to target collagen architecture in fibrotic skeletal muscle to reduce stiffness and promote tissue regeneration. | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $28,047 | May 1, 2024 | November 15, 2024 | WOHLGEMUTH, ROSS PAUL | reporter.nih.gov |
| Reactivation of an early embryonic program in FSHD and cancer | NIH | National Cancer Institute | 2022 | $23,676 | December 1, 2020 | March 31, 2022 | HAMM, DANIELLE | reporter.nih.gov |
| Skeletal Muscle: Development, Regeneration and Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $20,000 | May 6, 2021 | April 30, 2022 | CHEN, ELIZABETH H | reporter.nih.gov |
| Innovations in Myogenesis: From Molecular Mechanisms to Therapeutic Interventions | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $20,000 | July 2, 2025 | June 30, 2026 | AMBROSIO, FABRISIA | reporter.nih.gov |
| Coupling of muscle blind-dependent RNA processing to the circadian clock in neuronal homeostasis and sleep | NIH | National Heart, Lung, and Blood Institute | 2021 | $16,796 | March 1, 2019 | May 7, 2021 | PERELIS, MARK | reporter.nih.gov |
| 2022 Congenital Muscle Disease Scientific Symposium | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $15,000 | July 11, 2022 | June 30, 2023 | DZIEWCZAPOLSKI, GUSTAVO | reporter.nih.gov |
| Advances in Skeletal Muscle Growth, Repair and Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $15,000 | April 1, 2023 | March 31, 2024 | KYBA, MICHAEL | reporter.nih.gov |
| The role of BEX1 in translational control of muscle regeneration and reparative growth | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $11,763 | August 16, 2018 | December 31, 2021 | PETROSINO, JENNIFER MORGAN | reporter.nih.gov |
| 10th International Unstable Microsatellites and Human Disease Meeting | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $10,200 | December 1, 2024 | November 30, 2025 | RANUM, LAURA P.W | reporter.nih.gov |
| New Directions in Biology and Disease of Skeletal Muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $10,000 | September 1, 2020 | February 28, 2022 | MCNALLY, ELIZABETH M | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Minnesota | Minneapolis, MN | 18 | $23.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 14 | $15.5 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 8 | $12.5 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 9 | $10.3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 9 | $9.4 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 6 | $8.9 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 8 | $7.9 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 9 | $7.8 million | 0 | $0 |
| Washington University | Saint Louis, MO | 9 | $7.6 million | 0 | $0 |
| Duke University | Durham, NC | 5 | $7.4 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 5 | $7.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 9 | $6.7 million | 0 | $0 |
| University of Rochester | Rochester, NY | 7 | $6.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 5 | $6.5 million | 0 | $0 |
| Board of Regents, NSHE, obo University of Nevada, Reno | Reno, NV | 4 | $6.1 million | 0 | $0 |
| University of California at Davis | Davis, CA | 5 | $5.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 5 | $5.6 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 6 | $5.5 million | 0 | $0 |
| University of Washington | Seattle, WA | 4 | $5.4 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 5 | $5.2 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 5 | $4.9 million | 0 | $0 |
| Ohio State University | Columbus, OH | 6 | $4.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 4 | $4.6 million | 0 | $0 |
| Cornell University | Ithaca, NY | 3 | $4.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 2 | $3.9 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 3 | $3.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 4 | $3.8 million | 0 | $0 |
| Yale University | New Haven, CT | 3 | $3.7 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 2 | $3.7 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $3.5 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 7 | $3.5 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 2 | $3.2 million | 0 | $0 |
| Mirecule, Inc. | Gaithersburg, MD | 1 | $3.1 million | 0 | $0 |
| University of Delaware | Newark, DE | 1 | $3.1 million | 0 | $0 |
| Myogene Bio, LLC | San Diego, CA | 5 | $2.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 4 | $2.9 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 2 | $2.7 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 1 | $2.7 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 4 | $2.7 million | 0 | $0 |
| Strykagen Corporation | Reno, NV | 2 | $2.7 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 4 | $2.7 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 5 | $2.5 million | 0 | $0 |
| SUNY at Albany | Albany, NY | 2 | $2.5 million | 0 | $0 |
| Emory University | Atlanta, GA | 4 | $2.5 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 2 | $2.5 million | 0 | $0 |
| Curi Bio INC | Seattle, WA | 1 | $2.3 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 2 | $2.2 million | 0 | $0 |
| Myofinity Biosciences INC | Boston, MA | 3 | $2.2 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 1 | $2.1 million | 0 | $0 |
| SUNY at Binghamton | Binghamton, NY | 2 | $2 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 1 | $2 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 1 | $2 million | 0 | $0 |
| Myolex, Inc. | Brookline, MA | 1 | $2 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 1 | $2 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $1.9 million | 0 | $0 |
| Stanford University | Stanford, CA | 4 | $1.8 million | 0 | $0 |
| Kinea Bio, Inc. | Mukilteo, WA | 2 | $1.8 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 3 | $1.8 million | 0 | $0 |
| Wright State University | Dayton, OH | 1 | $1.8 million | 0 | $0 |
| Reveragen Biopharma, Inc. | Rockville, MD | 1 | $1.7 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 2 | $1.7 million | 0 | $0 |
| Tufts University | Medford, MA | 1 | $1.6 million | 0 | $0 |
| Myogenica Inc. | Saint Paul, MN | 1 | $1.6 million | 0 | $0 |
| Advertent Biotherapeutics, Inc. | East Lansing, MI | 2 | $1.5 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 1 | $1.5 million | 0 | $0 |
| University of Maine | Orono, ME | 3 | $1.5 million | 0 | $0 |
| Catholic University of America | Washington, DC | 1 | $1.4 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 2 | $1.4 million | 0 | $0 |
| Revidia Therapeutics, INC | Ellsworth, ME | 1 | $1.4 million | 0 | $0 |
| Upstate Medical University | Syracuse, NY | 1 | $1.2 million | 0 | $0 |
| University of Massachusetts Amherst | Amherst, MA | 1 | $1.2 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 1 | $1.2 million | 0 | $0 |
| Carle Foundation | Urbana, IL | 1 | $1.1 million | 0 | $0 |
| Texas A&M Engineering Experiment Station | College Station, TX | 1 | $1.1 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 1 | $1.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 2 | $1.1 million | 0 | $0 |
| Joslin Diabetes Center | Boston, MA | 1 | $1.1 million | 0 | $0 |
| Rbhs-Robert Wood Johnson Medical School | Piscataway, NJ | 2 | $1 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 3 | $1 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $1 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 2 | $1 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 3 | $980,755 | 0 | $0 |
| Boston College | Chestnut Hill, MA | 1 | $939,000 | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $935,104 | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 1 | $850,142 | 0 | $0 |
| Board of Trustees of Illinois State University | Normal, IL | 2 | $818,329 | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 1 | $766,280 | 0 | $0 |
| Iowa State University | Ames, IA | 2 | $729,947 | 0 | $0 |
| University of Kentucky | Lexington, KY | 2 | $721,704 | 0 | $0 |
| New York University | New York, NY | 1 | $644,779 | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $601,489 | 0 | $0 |
| University of South Florida | Tampa, FL | 1 | $568,465 | 0 | $0 |
| California State University San Marcos Corporation | San Marcos, CA | 2 | $546,500 | 0 | $0 |
| Lehigh University | Bethlehem, PA | 1 | $544,990 | 0 | $0 |
| Kennesaw State University | Kennesaw, GA | 1 | $542,000 | 0 | $0 |
| Augusta University | Augusta, GA | 1 | $499,954 | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 1 | $498,000 | 0 | $0 |
| Rowan University | Glassboro, NJ | 1 | $475,680 | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $401,250 | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 1 | $378,792 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 153 | $72,183,114 | 0 | $0 |
| 2024 | 160 | $73,010,778 | 0 | $0 |
| 2023 | 167 | $64,691,020 | 0 | $0 |
| 2022 | 158 | $59,326,696 | 0 | $0 |
| 2021 | 151 | $60,272,283 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.